相关实验视频

Updated: Sep 19, 2025

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Pharmacologic Induction of Epidermal Melanin and Protection Against Sunburn in a Humanized Mouse Model

Published on: September 7, 2013

更新了关于与5型化酶抑制剂相关的黑色素瘤风险的元分析

Michele Kreuz¹, Francisco Cezar A Moraes², Artur O M Lôbo³

¹Department of Medicine, Lutheran University of Brazil, Canoas.

Melanoma research

|June 6, 2025

概括

用于勃起功能障碍的固酶5型 (PDE5) 抑制剂与黑色素瘤的更高风险有关. 患有危险因素的患者应避免使用这些药物,因为这些药物可能导致致命的结果.

科学领域:

在瘤学瘤学.
皮肤病学皮肤病学
药理学药理学是指药理学的学科.

背景情况:

固酶5型 (PDE5) 抑制剂是勃起功能障碍的主要治疗方法.
自2011年以来,人们对与使用PDE5抑制剂相关的潜在黑色素瘤风险增加的担忧已经出现.
PDE5 抑制剂会影响与黑色素瘤发展相关的信号通路.

研究的目的:

系统地审查和分析现有文献,以调查PDE5抑制剂使用与患黑色素瘤的风险之间的关联.
量化PDE5抑制剂使用者的黑色素瘤的合并几率比率 (ORs) 和危险比率 (HRs).

主要方法:

在PubMed,Cochrane和Embase数据库中进行了系统的文献搜索.
在元分析中使用了随机效应模型来估计聚合的OR和HR.
使用I2统计数据评估异质性,并使用RStudio v4.4.2进行分析. 一个P值<0.05被认为是显著的.

主要成果:

分析了包括7,620,765名患者的8项研究,其中超过210万名患者在暴露于PDE5抑制剂的组中.
分析显示,使用PDE5抑制剂和增加黑色素瘤风险之间存在统计学意义上的关联 (OR: 1.60,P=0.009;HR: 1.10,P=0.005).
个别的PDE5抑制剂显示黑色素瘤发病率增加,但没有统计意义 (西尔德纳菲尔OR: 1.85,P=0.059;塔达拉菲尔OR: 1.54,P=0.203;瓦尔德纳菲尔OR: 1.16,P=0.391).

结论:

研究结果表明,使用PDE5抑制剂的人患黑色素瘤的风险在统计学上显著增加.
在使用PDE5抑制剂的患者中,患有潜在致命黑色素瘤的可能性更高.
患有皮肤癌史,黑色素瘤家族史或其他风险因素的患者应谨慎行事,并考虑避免使用PDE5抑制剂.

关键词:

黑色素瘤是一种黑色素瘤.这是一个元分析.固酶5型抑制剂的使用

更多相关视频

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA

Published on: December 19, 2019

A Melanoma Patient-Derived Xenograft Model

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...